NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic TargetElissa Andraos(Centre National de la Recherche Scientifique), Fabienne Meggetto(Centre National de la Recherche Scientifique)CancersJanuary 5, 202110.3390/cancers13010144Cited by 23SaveCiteExport RISWatch citationsRelated PapersALK+ALCLs induce cutaneous, HMGB-1–dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation|Blood|2012|32Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia|Blood|2010|32Generation of full-length circular RNA libraries for Oxford Nanopore long-read sequencing|PLoS ONE|2022|17